There are 119 resources available
2P - Sitravatinib + Tislelizumab in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC)
Presenter: Zhou Qing
Session: e-Poster Display session
3P - Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)
Presenter: Sumita Pradhan
Session: e-Poster Display session
1P - Sitravatinib + Tislelizumab in Patients with Anti-PD-(L)1 Refractory/Resistant Metastatic Non-small Cell Lung Cancer (NSCLC)
Presenter: No Gao
Session: e-Poster Display session
42P - BAL0891: a novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity
Presenter: Heidi Lane
Session: e-Poster Display session
43P - MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Presenter: Ticiana Leal
Session: e-Poster Display session
44P - A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
Presenter: Tak Yun
Session: e-Poster Display session
46P - AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2_ Inhibitor, for the Treatment of Renal Cell Carcinoma
Presenter: Kenneth Lawson
Session: e-Poster Display session
47P - Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder
Presenter: Sarah Rae
Session: e-Poster Display session
49P - Antitumor effects of cationic dendritic molecules and their complexes with microRNA in glioblastoma stem-like cells
Presenter: Nadezhda Knauer
Session: e-Poster Display session
20P - Immuno-modulating effects of hyperthermia on PD-L1 and NLRC5 in ovarian cancer
Presenter: maha fezza
Session: e-Poster Display session